Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform.

Biotechnology

Immunomic Therapeutics

Eric Winzer

Teri Heiland

Eric Winzer & Board Member

Frances Harrison

Cara Sholter

The Scientific Team at Immunomic Therapeutics drives the development and innovation of the UNITE platform by conducting cutting-edge research, designing clinical studies, and analyzing experimental data. This team, comprising leading experts and advisors, works collaboratively to advance the company's immunotherapy solutions from the laboratory to clinical application.

Scientific Team

Directors

Leadership Team

Scientific Team

About

Team members

Other teams at Immunomic Therapeutics

Directors

Leadership Team